Cargando…
Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study
BACKGROUND: Seventy percent of patients suffering from birch pollen allergy (BPA) develop a pollen‐related food allergy (prFA), especially to apples, due to a clinically relevant cross‐reactivity between the major allergen in birch Bet v 1 and Mal d 1 in apples. Therefore allergen‐specific immunothe...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127540/ https://www.ncbi.nlm.nih.gov/pubmed/33621436 http://dx.doi.org/10.1002/iid3.410 |
_version_ | 1783693967121973248 |
---|---|
author | Nothegger, Bettina Reider, Norbert Covaciu, Claudia E. Cova, Valentina Ahammer, Linda Eidelpes, Reiner Unterhauser, Jana Platzgummer, Stefan Raffeiner, Elisabeth Tollinger, Martin Letschka, Thomas Eisendle, Klaus |
author_facet | Nothegger, Bettina Reider, Norbert Covaciu, Claudia E. Cova, Valentina Ahammer, Linda Eidelpes, Reiner Unterhauser, Jana Platzgummer, Stefan Raffeiner, Elisabeth Tollinger, Martin Letschka, Thomas Eisendle, Klaus |
author_sort | Nothegger, Bettina |
collection | PubMed |
description | BACKGROUND: Seventy percent of patients suffering from birch pollen allergy (BPA) develop a pollen‐related food allergy (prFA), especially to apples, due to a clinically relevant cross‐reactivity between the major allergen in birch Bet v 1 and Mal d 1 in apples. Therefore allergen‐specific immunotherapy with fresh apples (AITA) could be a promising natural treatment of both BPA and prFA. OBJECTIVE: To assess the clinical efficacy of immunotherapy by daily apple consumption for patients with BPA and prFA. METHODS: A daily defined increasing amount of selected cultivars (Red Moon®, Pink Lady®, Topaz, Golden Delicious) was continuously consumed by 16 patients (12 female; median age; 50; range, 23–68 years), leading to increased intake of allergen over a period of at least 8 months. Specific IgE and IgG(4) to Bet v 1 and Mal d 1, conjunctival and oral provocation tests, skin reactivity, and the average daily rhinoconjunctivitis combined symptom and medication score (CSMS) were measured during the peak birch pollen season. RESULTS: After 8 months of therapy, patients showed increased tolerance to apples (p < .001) and a decreased skin reactivity to apples. Oral allergy syndrome to other birch prFA than apple also decreased (p < .05). Moreover, daily rhinoconjunctivitis CSMS declined by 34% (p < .001), as did conjunctival reactivity to birch pollen extract by 27% (p < .01), while specific IgG(4) to Mal d 1 and Bet v 1 increased (p < .01). |
format | Online Article Text |
id | pubmed-8127540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81275402021-05-21 Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study Nothegger, Bettina Reider, Norbert Covaciu, Claudia E. Cova, Valentina Ahammer, Linda Eidelpes, Reiner Unterhauser, Jana Platzgummer, Stefan Raffeiner, Elisabeth Tollinger, Martin Letschka, Thomas Eisendle, Klaus Immun Inflamm Dis Original Research BACKGROUND: Seventy percent of patients suffering from birch pollen allergy (BPA) develop a pollen‐related food allergy (prFA), especially to apples, due to a clinically relevant cross‐reactivity between the major allergen in birch Bet v 1 and Mal d 1 in apples. Therefore allergen‐specific immunotherapy with fresh apples (AITA) could be a promising natural treatment of both BPA and prFA. OBJECTIVE: To assess the clinical efficacy of immunotherapy by daily apple consumption for patients with BPA and prFA. METHODS: A daily defined increasing amount of selected cultivars (Red Moon®, Pink Lady®, Topaz, Golden Delicious) was continuously consumed by 16 patients (12 female; median age; 50; range, 23–68 years), leading to increased intake of allergen over a period of at least 8 months. Specific IgE and IgG(4) to Bet v 1 and Mal d 1, conjunctival and oral provocation tests, skin reactivity, and the average daily rhinoconjunctivitis combined symptom and medication score (CSMS) were measured during the peak birch pollen season. RESULTS: After 8 months of therapy, patients showed increased tolerance to apples (p < .001) and a decreased skin reactivity to apples. Oral allergy syndrome to other birch prFA than apple also decreased (p < .05). Moreover, daily rhinoconjunctivitis CSMS declined by 34% (p < .001), as did conjunctival reactivity to birch pollen extract by 27% (p < .01), while specific IgG(4) to Mal d 1 and Bet v 1 increased (p < .01). John Wiley and Sons Inc. 2021-02-23 /pmc/articles/PMC8127540/ /pubmed/33621436 http://dx.doi.org/10.1002/iid3.410 Text en © 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Nothegger, Bettina Reider, Norbert Covaciu, Claudia E. Cova, Valentina Ahammer, Linda Eidelpes, Reiner Unterhauser, Jana Platzgummer, Stefan Raffeiner, Elisabeth Tollinger, Martin Letschka, Thomas Eisendle, Klaus Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study |
title | Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study |
title_full | Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study |
title_fullStr | Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study |
title_full_unstemmed | Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study |
title_short | Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study |
title_sort | oral birch pollen immunotherapy with apples: results of a phase ii clinical pilot study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127540/ https://www.ncbi.nlm.nih.gov/pubmed/33621436 http://dx.doi.org/10.1002/iid3.410 |
work_keys_str_mv | AT notheggerbettina oralbirchpollenimmunotherapywithapplesresultsofaphaseiiclinicalpilotstudy AT reidernorbert oralbirchpollenimmunotherapywithapplesresultsofaphaseiiclinicalpilotstudy AT covaciuclaudiae oralbirchpollenimmunotherapywithapplesresultsofaphaseiiclinicalpilotstudy AT covavalentina oralbirchpollenimmunotherapywithapplesresultsofaphaseiiclinicalpilotstudy AT ahammerlinda oralbirchpollenimmunotherapywithapplesresultsofaphaseiiclinicalpilotstudy AT eidelpesreiner oralbirchpollenimmunotherapywithapplesresultsofaphaseiiclinicalpilotstudy AT unterhauserjana oralbirchpollenimmunotherapywithapplesresultsofaphaseiiclinicalpilotstudy AT platzgummerstefan oralbirchpollenimmunotherapywithapplesresultsofaphaseiiclinicalpilotstudy AT raffeinerelisabeth oralbirchpollenimmunotherapywithapplesresultsofaphaseiiclinicalpilotstudy AT tollingermartin oralbirchpollenimmunotherapywithapplesresultsofaphaseiiclinicalpilotstudy AT letschkathomas oralbirchpollenimmunotherapywithapplesresultsofaphaseiiclinicalpilotstudy AT eisendleklaus oralbirchpollenimmunotherapywithapplesresultsofaphaseiiclinicalpilotstudy |